Merus N.V., a pioneering biotechnology company headquartered in the Netherlands, focuses on the development of innovative bispecific antibody therapeutics. Founded in 2003, Merus has established itself as a leader in the biopharmaceutical industry, particularly in the fields of oncology and immunology. The company’s unique proprietary technology platform, known as the Biclonics® platform, enables the creation of bispecific antibodies that can simultaneously target multiple antigens, offering potential advantages in treating complex diseases. With a strong presence in Europe and North America, Merus has achieved significant milestones, including successful clinical trials and strategic partnerships with major pharmaceutical companies. The company’s commitment to advancing cancer treatment through its core products positions it as a notable player in the competitive biotech landscape, dedicated to improving patient outcomes and transforming therapeutic approaches.
How does Merus N.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Merus N.V.'s score of 28 is lower than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Merus N.V., headquartered in the Netherlands, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Merus N.V. may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the industry increasingly prioritises sustainability, it will be essential for Merus N.V. to consider developing and communicating its climate commitments to align with global standards and expectations.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Merus N.V. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
